Three large cups of coffee a day could help to slow the progress of Alzheimer’s disease and even reverse the condition, researchers say.
A daily dose of caffeine can suppress the degenerative processes in the brain that can lead to confusion and memory loss, a study in mice suggests.
Although drinking coffee has previously been linked to a lower risk of developing Alzheimer’s, this is the first study to suggest that caffeine can directly target the disease itself.
Alzheimer’s occurs when sticky clumps of abnormal protein in the brain called beta-amyloid build up to form plaques, impairing cognitive function. But mice with a rodent equivalent of the disease showed a 50 percent reduction in levels of amyloid protein in their brains after scientists spiked their drinking water with caffeine.
The change was reflected in their behavior as they developed better memories and quicker thinking.
In the study, published today in the Journal of Alzheimer’s Disease, researchers from the University of South Florida studied 55 mice that had been genetically engineered to develop dementia symptoms identical to those of Alzheimer’s as they aged. Before treatment the mice, which were aged 18 to 19 months — about 70 years in human terms — had performed poorly in the memory tests.
Half the animals were given a daily dose of caffeine in their drinking water — equivalent to a human consuming about six espresso shots or 500 milligrams of pure caffeine — while the other half continued to drink ordinary water.
By the end of the two-month study, the caffeine-drinking mice were performing far better on tests of memory and thinking than mice given water. Their memories were as sharp as those of healthy older mice without dementia.
The scientists found that when the mice drank caffeinated water their blood levels of beta amyloid protein fell quickly. More importantly, the same effect occurred in the brain. Almost half the abnormal protein previously seen when the brains of Alzheimer’s mice were examined had vanished after two months.
Professor Gary Arendash, a memory and ageing specialist who led the latest research, said that he wished to conduct human patient trials as soon as possible.